Skip to main content
Top
Published in: Journal of Nephrology 5/2018

01-10-2018 | Review

Nutritional therapy in autosomal dominant polycystic kidney disease

Authors: Biagio R. Di Iorio, Adamasco Cupisti, Claudia D’Alessandro, Antonio Bellasi, Vincenzo Barbera, Luca Di Lullo

Published in: Journal of Nephrology | Issue 5/2018

Login to get access

Abstract

CKD-related nutritional therapy (NT) is a crucial cornerstone of CKD patients’ treatment, but the role of NT has not been clearly investigated in autosomal dominant polycystic kidney disease (ADPKD). Several clinical studies have focused on new pharmacological approaches to delay cystic disease progression, but there are no data on dietary interventions in ADPKD patients. The aim of this paper is to analyze the evidence from the literature on the impact of five nutritional aspects (water, sodium, phosphorus, protein intake, and net acid load) in CKD-related ADPKD extrapolating—where information is unavailable—from what occurs in CKD non-ADPKD patients Sodium intake restriction could be useful in decreasing the growth rate of cysts. Although further evidence is needed, restriction of phosphorus and protein intake restriction represent cornerstones of the dietary support of renal non-ADPKD patients and common sense can guide their use. It could be also helpful to limit animal protein, increasing fruit and vegetables intake together with a full correction of metabolic acidosis. Finally, fluid intake may be recommended in the early stages of the disease, although it is not to be prescribed in the presence of moderate to severe reduction of renal function.
Literature
1.
go back to reference Liut F, Izzi C, Dallera N, Scolari F (2017) ADPKD e cuore. G Ital Nefrol 34(Suppl 69):119–130PubMed Liut F, Izzi C, Dallera N, Scolari F (2017) ADPKD e cuore. G Ital Nefrol 34(Suppl 69):119–130PubMed
2.
go back to reference Churchill DN, Bear JC, Morgan J, Payne RH, McManamon PJ, Gault MH (1984) Prognosis of adult onset polycystic kidney disease re-evaluated. Kidney Int 26:190–193CrossRef Churchill DN, Bear JC, Morgan J, Payne RH, McManamon PJ, Gault MH (1984) Prognosis of adult onset polycystic kidney disease re-evaluated. Kidney Int 26:190–193CrossRef
3.
go back to reference Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ (2003) Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant poly- cystic kidneys. Kidney Int 63:1983–1994CrossRef Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, Grantham JJ (2003) Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant poly- cystic kidneys. Kidney Int 63:1983–1994CrossRef
4.
go back to reference Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP (2004) Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279:40419–40430CrossRef Yamaguchi T, Wallace DP, Magenheimer BS, Hempson SJ, Grantham JJ, Calvet JP (2004) Calcium restriction allows cAMP activation of the B-Raf/ERK pathway, switching cells to a cAMP-dependent growth-stimulated phenotype. J Biol Chem 279:40419–40430CrossRef
5.
go back to reference Gattone VH 2nd, Wang X, Harris PC, Torres VE (2003) Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323–1326CrossRef Gattone VH 2nd, Wang X, Harris PC, Torres VE (2003) Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 9:1323–1326CrossRef
6.
go back to reference Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ (1997) Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 30:703–709CrossRef Yamaguchi T, Nagao S, Kasahara M, Takahashi H, Grantham JJ (1997) Renal accumulation and excretion of cyclic adenosine monophosphate in a murine model of slowly progressive polycystic kidney disease. Am J Kidney Dis 30:703–709CrossRef
7.
go back to reference Nagao S (2006) Increased Water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17:2220–2227CrossRef Nagao S (2006) Increased Water intake decreases progression of polycystic kidney disease in the PCK rat. J Am Soc Nephrol 17:2220–2227CrossRef
8.
go back to reference Hopp K, Wang X, Ye H, Irazabal MV, Harris PC, Torres VE (2015) Effects of hydration in rats and mice with polycystic kidney disease. Am J Physiol Renal Physiol 308(3):F261–F266CrossRef Hopp K, Wang X, Ye H, Irazabal MV, Harris PC, Torres VE (2015) Effects of hydration in rats and mice with polycystic kidney disease. Am J Physiol Renal Physiol 308(3):F261–F266CrossRef
9.
go back to reference Barash I, Ponda MP, Goldfarb DS, Skolnik EY (2010) A pilot clinical study to evaluate changes in urine osmolality and urine camp in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 5:693–697CrossRef Barash I, Ponda MP, Goldfarb DS, Skolnik EY (2010) A pilot clinical study to evaluate changes in urine osmolality and urine camp in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 5:693–697CrossRef
10.
go back to reference Higashihara E, Kikuo Nutahara K, Tanbo M, Hara H, Miyazaki I, Kobayashi H, Nitatori T (2014) Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant 29:1710–1719CrossRef Higashihara E, Kikuo Nutahara K, Tanbo M, Hara H, Miyazaki I, Kobayashi H, Nitatori T (2014) Does increased water intake prevent disease progression in autosomal dominant polycystic kidney disease? Nephrol Dial Transplant 29:1710–1719CrossRef
11.
go back to reference Amro OW, Paulus JK, Noubary F, Perrone RD (2016) Low-osmolar diet and adjusted water intake for vasopressin reduction in autosomal dominant polycystic kidney disease: a pilot randomized controlled trial. AM J Kidney Dis 68:882–891CrossRef Amro OW, Paulus JK, Noubary F, Perrone RD (2016) Low-osmolar diet and adjusted water intake for vasopressin reduction in autosomal dominant polycystic kidney disease: a pilot randomized controlled trial. AM J Kidney Dis 68:882–891CrossRef
12.
go back to reference El-Damanawi R, Harris T, Sandford RN, Karet Frankl FE, Hiemstra TF (2017) Patient survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey. Clin Kidney J 10:305–309CrossRef El-Damanawi R, Harris T, Sandford RN, Karet Frankl FE, Hiemstra TF (2017) Patient survey of current water Intake practices in autosomal dominant Polycystic kidney disease: the SIPs survey. Clin Kidney J 10:305–309CrossRef
13.
go back to reference Taylor JM, Hamilton-Reeves JM, Sullivan DK, Gibson CA, Creed C, Carlson SE, Wesson DE, Grantham JJ (2017) Diet and polycystic kidney disease: a pilot intervention study. Clin Nutr 36(2):458–466CrossRef Taylor JM, Hamilton-Reeves JM, Sullivan DK, Gibson CA, Creed C, Carlson SE, Wesson DE, Grantham JJ (2017) Diet and polycystic kidney disease: a pilot intervention study. Clin Nutr 36(2):458–466CrossRef
14.
go back to reference Wang CJ, Grantham JJ, Wetmore JB (2013) The medicinal use of water in renal disease. Kidney Int 84:45–53CrossRef Wang CJ, Grantham JJ, Wetmore JB (2013) The medicinal use of water in renal disease. Kidney Int 84:45–53CrossRef
15.
go back to reference Clark WF, Sontrop JM, Huang SH, Moist L, Bouby N, Bankir L (2016) Hydration and chronic kidney disease progression: a critical review of the evidence. Am J Nephrol 43:281–292CrossRef Clark WF, Sontrop JM, Huang SH, Moist L, Bouby N, Bankir L (2016) Hydration and chronic kidney disease progression: a critical review of the evidence. Am J Nephrol 43:281–292CrossRef
16.
go back to reference Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367(25):2407–2418CrossRef Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, Perrone RD, Krasa HB, Ouyang J, Czerwiec FS; TEMPO 3:4 Trial Investigators (2012) Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 367(25):2407–2418CrossRef
17.
go back to reference Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong AC, Ortiz A, Schaefer F, Torra R, Vanholder R, Więcek A, Zoccali C, Van Biesen W (2016). Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant 31(3):337–348CrossRef Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, Devuyst O, Drechsler C, Eckardt KU, Emma F, Knebelmann B, Le Meur Y, Massy ZA, Ong AC, Ortiz A, Schaefer F, Torra R, Vanholder R, Więcek A, Zoccali C, Van Biesen W (2016). Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice. Nephrol Dial Transplant 31(3):337–348CrossRef
18.
go back to reference Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, Miskulin DC, Rahbari Oskoui F, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Kelleher C, Schrier RW (2010) HALT T polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 5(1):102–109CrossRef Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, Miskulin DC, Rahbari Oskoui F, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Kelleher C, Schrier RW (2010) HALT T polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 5(1):102–109CrossRef
19.
go back to reference Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF (2017) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 91(2):493–500CrossRef Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, Braun WE, Steinman TI, Brosnahan G, Hogan MC, Rahbari FF, Grantham JJ, Bae KT, Moore CG, Flessner MF (2017) Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int 91(2):493–500CrossRef
20.
go back to reference Taylor JM, Ptomey L, Hamilton-Reeves JM, Sullivan DK, Creed C, Carlson SE, Wesson DE, Grantham JJ, Gibson CA (2016) Experiences and perspectives of polycystic kidney disease patients following a diet of reduced osmoles, protein, and acid precursors supplemented with water: a qualitative study. PLoS One 11(8):e0161043CrossRef Taylor JM, Ptomey L, Hamilton-Reeves JM, Sullivan DK, Creed C, Carlson SE, Wesson DE, Grantham JJ, Gibson CA (2016) Experiences and perspectives of polycystic kidney disease patients following a diet of reduced osmoles, protein, and acid precursors supplemented with water: a qualitative study. PLoS One 11(8):e0161043CrossRef
21.
go back to reference Rebholz CM, Crews DC, Grams ME, Steffen LM, Levey AS, Miller ER 3rd, Appel LJ, Coresh J (2016) DASH (dietary approaches to stop hypertension) diet and risk of subsequent kidney disease. Am J Kidney Dis 68(6):853–861CrossRef Rebholz CM, Crews DC, Grams ME, Steffen LM, Levey AS, Miller ER 3rd, Appel LJ, Coresh J (2016) DASH (dietary approaches to stop hypertension) diet and risk of subsequent kidney disease. Am J Kidney Dis 68(6):853–861CrossRef
22.
go back to reference Nomura K, Asayama K, Jacobs L, Thijs L, Staessen JA (2017) Renal function in relation to sodium intake: a quantitative review of the literature. Kidney Int 92(1):67–78CrossRef Nomura K, Asayama K, Jacobs L, Thijs L, Staessen JA (2017) Renal function in relation to sodium intake: a quantitative review of the literature. Kidney Int 92(1):67–78CrossRef
23.
go back to reference Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G; Cholesterol And Recurrent Events Trial Investigators (2005) Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112(17):2627–2633CrossRef Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G; Cholesterol And Recurrent Events Trial Investigators (2005) Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 112(17):2627–2633CrossRef
24.
go back to reference Chang AR, Lazo M, Appel LJ, Gutiérrez OM, Grams ME (2014) High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III. Am J Clin Nutr 99(2):320–327CrossRef Chang AR, Lazo M, Appel LJ, Gutiérrez OM, Grams ME (2014) High dietary phosphorus intake is associated with all-cause mortality: results from NHANES III. Am J Clin Nutr 99(2):320–327CrossRef
25.
go back to reference Gutiérrez OM (2013) The connection between dietary phosphorus, cardiovascular disease, and mortality: where we stand and what we need to know. Adv Nutr. 4(6):723–729CrossRef Gutiérrez OM (2013) The connection between dietary phosphorus, cardiovascular disease, and mortality: where we stand and what we need to know. Adv Nutr. 4(6):723–729CrossRef
26.
go back to reference Tonelli M (2013) Serum phosphorus in people with chronic kidney disease: you are what you eat. Kidney Int 84(5):871–873CrossRef Tonelli M (2013) Serum phosphorus in people with chronic kidney disease: you are what you eat. Kidney Int 84(5):871–873CrossRef
27.
go back to reference O’Seaghdha CM, Hwang SJ, Muntner P, Melamed ML, Fox CS (2011) Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 26(9):2885–2890CrossRef O’Seaghdha CM, Hwang SJ, Muntner P, Melamed ML, Fox CS (2011) Serum phosphorus predicts incident chronic kidney disease and end-stage renal disease. Nephrol Dial Transplant 26(9):2885–2890CrossRef
28.
go back to reference De Rechter S, Bacchetta J, Godefroid N, Dubourg L, Cochat P, Maquet J, Raes A, De Schepper J, Vermeersch P, Van Dyck M, Levtchenko E, D’Haese P, Evenepoel P, Mekahli D (2017) Evidence for bone and mineral metabolism alterations in children with autosomal dominant polycystic kidney disease. J Clin Endocrinol Metab 102(11):4210–4217CrossRef De Rechter S, Bacchetta J, Godefroid N, Dubourg L, Cochat P, Maquet J, Raes A, De Schepper J, Vermeersch P, Van Dyck M, Levtchenko E, D’Haese P, Evenepoel P, Mekahli D (2017) Evidence for bone and mineral metabolism alterations in children with autosomal dominant polycystic kidney disease. J Clin Endocrinol Metab 102(11):4210–4217CrossRef
29.
go back to reference Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, Bellasi A; INDEPENDENT Study Investigators (2013) Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 62(4):771–778CrossRef Di Iorio B, Molony D, Bell C, Cucciniello E, Bellizzi V, Russo D, Bellasi A; INDEPENDENT Study Investigators (2013) Sevelamer versus calcium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 62(4):771–778CrossRef
30.
go back to reference Di Iorio B, Bellasi A, Russo D; INDEPENDENT Study Investigators (2012) Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 7(3):487–493CrossRef Di Iorio B, Bellasi A, Russo D; INDEPENDENT Study Investigators (2012) Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol. 7(3):487–493CrossRef
31.
go back to reference Pérez-Torres A, González Garcia ME, San José-Valiente B, Bajo Rubio MA, Celadilla Diez O, López-Sobaler AM, Selgas R (2017) Protein-energy wasting syndrome in advanced chronic kidney disease: prevalence and specific clinical characteristics. Nefrologia Jul 26. pii:S0211–6995(17)30141-8. https://doi.org/10.1016/j.nefro.2017.06.004 [Epub ahead of print]CrossRef Pérez-Torres A, González Garcia ME, San José-Valiente B, Bajo Rubio MA, Celadilla Diez O, López-Sobaler AM, Selgas R (2017) Protein-energy wasting syndrome in advanced chronic kidney disease: prevalence and specific clinical characteristics. Nefrologia Jul 26. pii:S0211–6995(17)30141-8. https://​doi.​org/​10.​1016/​j.​nefro.​2017.​06.​004 [Epub ahead of print]CrossRef
32.
go back to reference Cupisti A, D’Alessandro C, Finato V, Del Corso C, Catania B, Caselli GM, Egidi MF (2017) Assessment of physical activity, capacity and nutritional status in elderly peritoneal dialysis patients. BMC Nephrol 18(1):180CrossRef Cupisti A, D’Alessandro C, Finato V, Del Corso C, Catania B, Caselli GM, Egidi MF (2017) Assessment of physical activity, capacity and nutritional status in elderly peritoneal dialysis patients. BMC Nephrol 18(1):180CrossRef
33.
go back to reference Aukema HM, Ogborn MR, Tomobe K, Takahashi H, Hibino T, Holub BJ. (1992) Effects of dietary protein restriction and oil type on the early progression of murine polycystic kidney disease. Kidney Int. 42(4):837–842CrossRef Aukema HM, Ogborn MR, Tomobe K, Takahashi H, Hibino T, Holub BJ. (1992) Effects of dietary protein restriction and oil type on the early progression of murine polycystic kidney disease. Kidney Int. 42(4):837–842CrossRef
34.
go back to reference Aukema HM, Housini I, Rawling JM (1999) Dietary soy protein effects on inherited polycystic kidney disease are influenced by gender and protein level. J Am Soc Nephrol 10(2):300–308PubMed Aukema HM, Housini I, Rawling JM (1999) Dietary soy protein effects on inherited polycystic kidney disease are influenced by gender and protein level. J Am Soc Nephrol 10(2):300–308PubMed
35.
go back to reference Tomobe K, Philbrick D, Aukema HM, Clark WF, Ogborn MR, Parbtani A, Takahashi H, Holub BJ (1994) Early dietary protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease. J Am Soc Nephrol 5(6):1355–1360PubMed Tomobe K, Philbrick D, Aukema HM, Clark WF, Ogborn MR, Parbtani A, Takahashi H, Holub BJ (1994) Early dietary protein restriction slows disease progression and lengthens survival in mice with polycystic kidney disease. J Am Soc Nephrol 5(6):1355–1360PubMed
36.
go back to reference Barsotti G, Cupisti A, Moriconi L, Cozza V, Falbo E, Gattai V, Pozzolini L, Meola M (1995) Effects of reduced protein intake in rats with congenital polycystic kidney without renal failure. Contrib Nephrol 115:137–140CrossRef Barsotti G, Cupisti A, Moriconi L, Cozza V, Falbo E, Gattai V, Pozzolini L, Meola M (1995) Effects of reduced protein intake in rats with congenital polycystic kidney without renal failure. Contrib Nephrol 115:137–140CrossRef
37.
go back to reference Ogborn MR, Nitschmann E, Weiler HA, Bankovic-Calic N (2000) Modification of polycystic kidney disease and fatty acid status by soy protein diet. Kidney Int 57(1):159–166CrossRef Ogborn MR, Nitschmann E, Weiler HA, Bankovic-Calic N (2000) Modification of polycystic kidney disease and fatty acid status by soy protein diet. Kidney Int 57(1):159–166CrossRef
38.
go back to reference Yamaguchi T, Devassy JG, Monirujjaman M, Gabbs M, Aukema HM (2016) Lack of Benefit of early intervention with dietary flax and fish oil and soy protein in orthologous rodent models of human hereditary polycystic kidney disease. PLoS One 11(5):e0155790CrossRef Yamaguchi T, Devassy JG, Monirujjaman M, Gabbs M, Aukema HM (2016) Lack of Benefit of early intervention with dietary flax and fish oil and soy protein in orthologous rodent models of human hereditary polycystic kidney disease. PLoS One 11(5):e0155790CrossRef
39.
go back to reference Warner G, Hein KZ, Nin V, Edwards M, Chini CC, Hopp K, Harris PC, Torres VE, Chini EN (2016) Food restriction ameliorates the development of polycystic kidney disease. J Am Soc Nephrol 27(5):1437–1447CrossRef Warner G, Hein KZ, Nin V, Edwards M, Chini CC, Hopp K, Harris PC, Torres VE, Chini EN (2016) Food restriction ameliorates the development of polycystic kidney disease. J Am Soc Nephrol 27(5):1437–1447CrossRef
40.
go back to reference Kipp KR, Rezaei M, Lin L, Dewey EC, Weimbs T (2016) A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease. Am J Physiol Renal Physiol 310(8):F726-F731CrossRef Kipp KR, Rezaei M, Lin L, Dewey EC, Weimbs T (2016) A mild reduction of food intake slows disease progression in an orthologous mouse model of polycystic kidney disease. Am J Physiol Renal Physiol 310(8):F726-F731CrossRef
41.
go back to reference Peng CY, Sankaran D, Ogborn MR, Aukema HM (2009) Dietary soy protein selectively reduces renal prostanoids and cyclooxygenases in polycystic kidney disease. Exp Biol Med (Maywood) 234(7):737–743CrossRef Peng CY, Sankaran D, Ogborn MR, Aukema HM (2009) Dietary soy protein selectively reduces renal prostanoids and cyclooxygenases in polycystic kidney disease. Exp Biol Med (Maywood) 234(7):737–743CrossRef
42.
go back to reference Klahr S, Breyer JA, Beck GJ, Dennis VW, Hartman JA, Roth D, Steinman TI, Wang SR, Yamamoto ME (1995) Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol 5(12)2037–2034PubMed Klahr S, Breyer JA, Beck GJ, Dennis VW, Hartman JA, Roth D, Steinman TI, Wang SR, Yamamoto ME (1995) Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol 5(12)2037–2034PubMed
43.
go back to reference Choukroun G, Itakura Y, Albouze G, Christophe JL, Man NK, Grünfeld JP, Jungers P (1995) Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 6(6):1634–1642PubMed Choukroun G, Itakura Y, Albouze G, Christophe JL, Man NK, Grünfeld JP, Jungers P (1995) Factors influencing progression of renal failure in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 6(6):1634–1642PubMed
44.
go back to reference Yamamoto J, Nishio S, Hattanda F, Nakazawa D, Kimura T, Sata M, Makita M, Ishikawa Y, Atsumi T (2017) Branched-chain amino acids enhance cyst development in autosomal dominant polycystic kidney disease. Kidney Int 92(2):377–387CrossRef Yamamoto J, Nishio S, Hattanda F, Nakazawa D, Kimura T, Sata M, Makita M, Ishikawa Y, Atsumi T (2017) Branched-chain amino acids enhance cyst development in autosomal dominant polycystic kidney disease. Kidney Int 92(2):377–387CrossRef
45.
go back to reference Di Iorio BR, Di Micco L, Marzocco S, De Simone E, De Blasio A, Sirico ML, Nardone L, On Behalf Of Ubi Study Group (2017) Very low-protein diet (VLPD) reduces metabolic acidosis in subjects with chronic kidney disease: the “Nutritional Light Signal” of the Renal Acid Load. Nutrients 9(1) Di Iorio BR, Di Micco L, Marzocco S, De Simone E, De Blasio A, Sirico ML, Nardone L, On Behalf Of Ubi Study Group (2017) Very low-protein diet (VLPD) reduces metabolic acidosis in subjects with chronic kidney disease: the “Nutritional Light Signal” of the Renal Acid Load. Nutrients 9(1)
46.
go back to reference Goraya N, Simoni J, Jo CH, Wesson DE. (2013) A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate. Clin J Am Soc Nephrol. 8(3):371–381CrossRef Goraya N, Simoni J, Jo CH, Wesson DE. (2013) A comparison of treating metabolic acidosis in CKD stage 4 hypertensive kidney disease with fruits and vegetables or sodium bicarbonate. Clin J Am Soc Nephrol. 8(3):371–381CrossRef
47.
go back to reference Goraya N, Wesson DE (2013) Does correction of metabolic acidosis slow chronic kidney disease progression? Curr Opin Nephrol Hypertens 22(2):193–197CrossRef Goraya N, Wesson DE (2013) Does correction of metabolic acidosis slow chronic kidney disease progression? Curr Opin Nephrol Hypertens 22(2):193–197CrossRef
48.
go back to reference Bissler JJ. (2015) Therapies for polycystic kidney disease. Curr Opin Pediatr. 27(2):227–232CrossRef Bissler JJ. (2015) Therapies for polycystic kidney disease. Curr Opin Pediatr. 27(2):227–232CrossRef
49.
go back to reference Di Iorio B, Aucella F, Conte G, Cupisti A, Santoro D (2012) A prospective, multicenter, randomized, controlled study: the correction of metabolic acidosis with use of bicarbonate in Chronic Renal Insufficiency (UBI) Study. J Nephrol. 25(3):437–440CrossRef Di Iorio B, Aucella F, Conte G, Cupisti A, Santoro D (2012) A prospective, multicenter, randomized, controlled study: the correction of metabolic acidosis with use of bicarbonate in Chronic Renal Insufficiency (UBI) Study. J Nephrol. 25(3):437–440CrossRef
50.
go back to reference Remer T, Manz F (1994) Estimation of the renal net acid excretion by adults consuming diets containing variable amounts of protein. Am J Clin Nutr 59:1356–1361CrossRef Remer T, Manz F (1994) Estimation of the renal net acid excretion by adults consuming diets containing variable amounts of protein. Am J Clin Nutr 59:1356–1361CrossRef
51.
go back to reference Frassetto LA, Todd KM, Morris RJC, Sebastian A (1998) Estimation of net endogenous noncarbonic acid production in humans from diet potassium and protein contents. Am J Clin Nutr 68:576–583CrossRef Frassetto LA, Todd KM, Morris RJC, Sebastian A (1998) Estimation of net endogenous noncarbonic acid production in humans from diet potassium and protein contents. Am J Clin Nutr 68:576–583CrossRef
52.
go back to reference Tanner GA (1998) Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease. J Am Soc Nephrol 9(7):1242–1248PubMed Tanner GA (1998) Potassium citrate/citric acid intake improves renal function in rats with polycystic kidney disease. J Am Soc Nephrol 9(7):1242–1248PubMed
53.
go back to reference Torres VE, Keith DS, Offord KP, Kon SP, Wilson DM (1994) Renal ammonia in autosomal dominant polycystic kidney disease. Kidney Int 45(6):1745–1753CrossRef Torres VE, Keith DS, Offord KP, Kon SP, Wilson DM (1994) Renal ammonia in autosomal dominant polycystic kidney disease. Kidney Int 45(6):1745–1753CrossRef
54.
go back to reference D’Alessandro C, Piccoli GB, Calella P, Brunori G, Pasticci F, Egidi MF, Capizzi I, Bellizzi V, Cupisti A (2016) “Dietaly”: practical issues for the nutritional management of CKD patients in Italy. BMC Nephrol 17(1):102CrossRef D’Alessandro C, Piccoli GB, Calella P, Brunori G, Pasticci F, Egidi MF, Capizzi I, Bellizzi V, Cupisti A (2016) “Dietaly”: practical issues for the nutritional management of CKD patients in Italy. BMC Nephrol 17(1):102CrossRef
55.
go back to reference Magistroni R, Boletta A (2017) Defective glycolysis and the use of 2-deoxy-D-glucose in polycystic kidney disease: from animal models to humans. J Nephrol 30(4):511–519CrossRef Magistroni R, Boletta A (2017) Defective glycolysis and the use of 2-deoxy-D-glucose in polycystic kidney disease: from animal models to humans. J Nephrol 30(4):511–519CrossRef
Metadata
Title
Nutritional therapy in autosomal dominant polycystic kidney disease
Authors
Biagio R. Di Iorio
Adamasco Cupisti
Claudia D’Alessandro
Antonio Bellasi
Vincenzo Barbera
Luca Di Lullo
Publication date
01-10-2018
Publisher
Springer International Publishing
Published in
Journal of Nephrology / Issue 5/2018
Print ISSN: 1121-8428
Electronic ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-018-0470-x

Other articles of this Issue 5/2018

Journal of Nephrology 5/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine